

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Pharmaceutical preparation that contains at least one emulsifier, at least one auxiliary emulsifier and/or solvent as well as at least one lipid, characterized in that the mass ratio of emulsifier to auxiliary emulsifier and/or solvent (Smix) is 1:1 to 9:1 and the total lipid proportion is > 0% (m/m), whereby this preparation at least partially inhibits at least one intestinal enzyme and/or at least one intestinal efflux system.
2. (Original) Pharmaceutical preparation according to claim 1, wherein the Smix is 3:1 to 9:1.
3. (Original) Pharmaceutical preparation according to claim 3, wherein the Smix is 9:1.
4. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1-3~~ Claim 1, wherein the total lipid proportion is 10-50% (m/v).
5. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1-4~~ Claim 1, whereby intestinal enzymes originate from the group of 17 $\beta$ -hydroxy-steroid-dehydrogenase or the cytochrome monooxygenases and intestinal efflux systems from the group of P-glycoproteins.
6. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1 to 5~~ Claim 1, wherein the emulsifier contains PEG-40-hydrogenated castor oil (Cremophor<sup>®</sup>RH40), PEG-35 castor oil (Cremophor<sup>®</sup>EL) or PEG-

- 400-monoricinoleate (Estax<sup>®</sup>54).
7. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1–6~~ Claim 1, wherein the auxiliary emulsifier and/or the solvent contains glyceryl monocaprylate > 80% (m/m) (Imwitor<sup>®</sup>308) or diethylene glycol monoethyl ether (Transcitol<sup>®</sup>P).
  8. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1–7~~ Claim 1, wherein the lipid contains triglycerides, fatty oils or waxes.
  9. (Original) Pharmaceutical preparation according to claim 8, wherein the triglyceride contains mid-chain triglycerides (Miglyol<sup>®</sup>).
  10. (Original) Pharmaceutical preparation according to claim 8, wherein the fatty oil contains castor oil, olive oil, corn oil, soybean oil, sunflower oil, peanut oil, walnut oil or diestel oil.
  11. (Original) Pharmaceutical preparation according to claim 8, wherein the wax contains ethyl oleate or isopropyl myristate.
  12. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 1 to 11~~ Claim 1, wherein the preparation contains in addition at least one pharmaceutical substance.
  13. (Original) Pharmaceutical preparation according to claim 12, wherein the pharmaceutical substance is lipophilic and/or water-insoluble or hydrophilic.
  14. (Currently Amended) Pharmaceutical preparation according to ~~claim 12 or 13~~ Claim 1, wherein at least one pharmaceutical substance is a substrate of at least

- one intestinal enzyme and/or an intestinal efflux system.
15. (Original) Pharmaceutical preparation according to claim 14, wherein at least one intestinal enzyme originates from the group of 17 $\beta$ -hydroxy-steroid-dehydrogenases and/or cytochrome-monooxygenases.
16. (Original) Pharmaceutical preparation according to claim 15, wherein at least one intestinal enzyme is 17 $\beta$ -HSD 2 and/or originates from the group of cytochrome P 450 3A-monooxygenases.
17. (Original) Pharmaceutical preparation according to claim 14, wherein at least one intestinal efflux system originates from the group of P-gp- transporter systems.
18. (Currently Amended) Pharmaceutical preparation according to ~~one of claims 12 to 17~~ Claim 1, wherein at least one pharmaceutical substance is a steroid.
19. (Original) Pharmaceutical preparation according to claim 18, wherein the steroid in 17-position of the sterane skeleton contains a secondary, beta-position hydroxyl group.
20. (Currently Amended) Pharmaceutical preparation according to ~~claim 18 or 19~~ Claim 1, wherein the steroid is an estrogen, an antiestrogen or an androgen.
21. (Currently Amended) Pharmaceutical preparation according to ~~at least one of claims 18 to 20~~ Claim 1, wherein the steroid 11- $\alpha$ -hydroxynandrolone, 16- $\alpha$ -fluoroestradiol, 16- $\alpha$ -idoestradiol, 16- $\beta$ -fluoroestradiol, 2,4-dibromoestradiol, 2-chloroestradiol, 2-ethoxyestradiol, 2-fluoroestradiol, 2-hydroxyestriol, 2-methoxyestradiol, 2-methoxyestriol, 2-methoxymethylestradiol, 3-

methoxyestriol, 4-bromoestradiol, 4-chloroestradiol, 4-fluoro-17 $\beta$ -estradiol, 4-hydroxyestradiol, 4-hydroxytestosterone, 4-methoxyestradiol, 5- $\beta$ -androstan-17 $\beta$ -ol-3-one, 6- $\alpha$ -hydroxyestradiol, 3 $\alpha$ , 17 $\beta$ -androstanediol, 3 $\beta$ ,17 $\beta$ -androstanediol, androstanolone, androstenediol, bolanediol, bolazine, boldenone, clostebol, dacuronium bromide, 17-deacetylpancuronium, dideactetylvecuronium, vecuronium, 17 $\beta$ -dihydroequilin, 5 $\alpha$ -dihydro-19-nortestosterone, 16 $\alpha$ -bromo-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 16 $\alpha$ -chloro-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 16 $\alpha$ -iodo-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 16 $\alpha$ -bromo-7 $\alpha$ -(N-butyl, N-methyl-undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, epiestriol, epitiostanol, estetrol, estradiol, estradiol-3-glucuronide, estradiol-3-methylether, estradiol-3-sulfate, estradiol-3-benzoate, estradiol-3-hexahydrobenzoate, estramustine, estriol, estriol-3-glucuronide, estriol-3-sulfate, estriol-16-glucuronide, estrynamine, 17 $\beta$ -hydroxy-6-methylene-androsta-1,4-dien-3-one, fulvestrant, 1-hydroxy-17 $\beta$ -estradiol, 2-hydroxy-17 $\beta$ -estradiol, 4-hydroxy-17 $\beta$ -estradiol, 6-hydroxy-17 $\beta$ -estradiol, 7-hydroxy-17 $\beta$ -estradiol, 15-hydroxy-17 $\beta$ -estradiol, 18-hydroxy-17 $\beta$ -estradiol, 7-(N-butyl-undecanamide)-3,17 $\beta$ -estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 7 $\alpha$ -(N-butyl-undecanamide)-3,17 $\beta$ -estra-1,3,5(10)-triene-3,17 $\beta$ -diol, estra-1,3,5(10)-triene-7 $\beta$ -(N-butyl)undecanamide-3,17 $\beta$ -diol, 7 $\alpha$ -(N-butyl, N-methyl-

undecanamide)-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, inocoterone, estra-3-sulfamate-1,3,5(10),7-tetraene-3,17 $\beta$ -diol, cycloprop[14S,15 $\beta$ ]-3',15-dihydro-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, estra-1,3,5(10)-triene-3-sulfamate-17 $\beta$ -ol, mesterolone, methenolone, 16-methyleneestradiol, metogest, nandrolone, nisterime, norclostebol, 3-octyloxy-5 $\alpha$ -androst-3-en-17 $\beta$ -ol, estradiol-17-phenylpropionate-estradiol-benzoate mixture, 7-ethyl-nandrolone, 11 $\beta$ -chloromethyl-estra-3,17 $\beta$ -diol, piperidinium-1-[(2 $\beta$ ,3 $\alpha$ ,5 $\alpha$ ,16 $\beta$ ,17 $\beta$ )-3,17-dihydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl-bromide, 17-deacetylrocuronium, oxendolone, 11 $\alpha$ -methoxy-7 $\alpha$ -methyl-estra-3-17 $\beta$ -diol, quinestradol, 17 $\beta$ -hydroxy-7 $\alpha$ -methyl-androst-5-en-3-one, 11 $\alpha$ -ethenyl-estra-3,17 $\beta$ -diol, 11 $\beta$ -[4(dimethylamino)phenyl]-estra-3, 17 $\beta$ -diol, 7 $\alpha$ -{4-[2-(dimethylamino)ethoxy]phenyl}-estra-3,17 $\beta$ -diol, 11 $\beta$ -{4-[(methylsulfonyl)oxy]phenyl}-estra-3,17 $\beta$ -diol, 11 $\beta$ -{4-[[5-[(4,4,5,5,5-pentafluoropentyl)sulfonyl]pentyl]oxy]phenyl}-estra-3,17 $\beta$ -diol, 17 $\beta$ -dihydroxy-9 $\alpha$ -fluoro-11 $\beta$ -androsta-1,4-dien-3-one, stenbolone, cycloprop[14R,15 $\alpha$ ]estra-3',15-dihydro-3-methoxy-1,3,5(10)-trien-17 $\beta$ -ol, cycloprop[14S,15 $\beta$ ]estra-3',15-dihydro-3-methoxy-1,3,5(10)-trien-17 $\beta$ -ol, testosterone, trestolone, trilostane, 13 $\beta$ -ethyl-8 $\alpha$ -gona-1,3,5(10)-triene-3,16 $\alpha$ ,17 $\beta$ -triol, 13 $\beta$ -ethyl-8 $\beta$ -gona-1,3,5(10)-triene-3,16 $\alpha$ ,17 $\beta$ -triol, estra-2-{tricyclo[3.3.1.13,7]decyl}-1,3,5(10)-triene-3,17 $\beta$ -diol, ent-estradiol, 8 $\beta$ -vinyl-estradiol, 11 $\beta$ -fluoro-7 $\alpha$ -{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-

- propylamino]pentyl}-estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 11 $\beta$ -fluoro-7 $\alpha$ -{5-[methyl-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)amino]pentyl}estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 11 $\beta$ -fluoro-17 $\alpha$ -methyl-7 $\alpha$ -{5-[methyl-(8,8,9,9,9-pentafluoronyl)amino]-pentyl}estra-1,3,5(10)-triene-3,17 $\beta$ -diol, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 17 $\beta$ -hydroxy-7 $\alpha$ -methyl-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 4-chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 4,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androst-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androsta-1,4-dien-3-one, 4-chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-androsta-1,4-dien-3-one, 4-chloro-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 7 $\beta$ -hydroxy-7 $\alpha$ -methyl-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 4,17 $\beta$ -dihydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estr-4-en-3-one, 17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-estra-4,9,11-trien-3-one, 3-ethyl-17 $\beta$ -hydroxy-14 $\alpha$ ,15 $\alpha$ -methylene-gon-4-en-3-one, 17 $\alpha$ - $\beta$ -hydroxy-17 $\alpha$ -homoandrosta-4,15-dien-3-one, 1"-mesyl-17 $\alpha$ -(trifluoromethyl)-1'H-pyrazol[4",5':2,3]androst-4-en-17 $\beta$ -ol.
22. (Currently Amended) Use of a pharmaceutical preparation according to ~~at least one of claims 1 to 21~~ Claim 1 for the production of a peroral pharmaceutical agent for inhibiting at least one intestinal enzyme and/or at least one intestinal efflux system.
23. (Original) Use of a pharmaceutical preparation according to claim 22, wherein

- at least one intestinal enzyme originates from the group of 17 $\beta$ -hydroxy-steroid-dehydrogenases and/or cytochrome-P450-monoxygenases.
24. (Original) Use of a pharmaceutical preparation according to claim 23, wherein at least one intestinal enzyme is 17 $\beta$ -HSD 2 and/or originates from the group of cytochrome-P450-3A-monoxygenases.
25. (Original) Use of a pharmaceutical preparation according to claim 22, wherein at least one intestinal efflux system is a P-gp- transporter.
26. (Currently Amended) Use of a pharmaceutical preparation according to ~~at least one of claims 22 to 25~~ Claim 1, wherein the pharmaceutical agent comes from the group of therapeutic agents, prophylactic agents or diagnostic agents.
27. (Currently Amended) Process for increasing the bioavailability of pharmaceutical substances that are to be administered perorally, wherein a pharmaceutical preparation contains a pharmaceutical substance and is administered perorally according to ~~at least one of claims 1 to 21~~ Claim 1.